CN114903961A - Composition for treating osteoarthropathy and application thereof - Google Patents
Composition for treating osteoarthropathy and application thereof Download PDFInfo
- Publication number
- CN114903961A CN114903961A CN202210531563.8A CN202210531563A CN114903961A CN 114903961 A CN114903961 A CN 114903961A CN 202210531563 A CN202210531563 A CN 202210531563A CN 114903961 A CN114903961 A CN 114903961A
- Authority
- CN
- China
- Prior art keywords
- parts
- ethanol
- filtrate
- enzymolysis
- chitosan oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 206010057178 Osteoarthropathies Diseases 0.000 title claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 90
- 239000000706 filtrate Substances 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 29
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 25
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 25
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 16
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 15
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 14
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 14
- 239000011347 resin Substances 0.000 claims abstract description 14
- 229920005989 resin Polymers 0.000 claims abstract description 14
- 235000013976 turmeric Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims abstract description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 24
- 241000881711 Acipenser sturio Species 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 18
- 239000004365 Protease Substances 0.000 claims description 13
- 108010059892 Cellulase Proteins 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 229940106157 cellulase Drugs 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 108090000526 Papain Proteins 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 10
- 229940055729 papain Drugs 0.000 claims description 10
- 235000019834 papain Nutrition 0.000 claims description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 10
- 230000008961 swelling Effects 0.000 claims description 10
- 201000008482 osteoarthritis Diseases 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036407 pain Effects 0.000 abstract description 30
- 208000002193 Pain Diseases 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 23
- 241000699670 Mus sp. Species 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 239000003480 eluent Substances 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- 238000010992 reflux Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 9
- 241000407170 Curcuma Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000009835 boiling Methods 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000001503 joint Anatomy 0.000 description 5
- 206010065390 Inflammatory pain Diseases 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 229940036811 bone meal Drugs 0.000 description 3
- 239000002374 bone meal Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000270 Ficain Proteins 0.000 description 2
- 208000005137 Joint instability Diseases 0.000 description 2
- 206010023230 Joint stiffness Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019836 ficin Nutrition 0.000 description 2
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000036441 nociceptive stimulation Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of biological medicines and health care products, and particularly relates to a composition for treating osteoarthropathy and application thereof. The raw materials of the composition comprise the following components: kudzu root, turmeric, chitosan oligosaccharide, fishbone powder and hyaluronic acid. The preparation method comprises extracting radix Puerariae and Curcuma rhizome with water to obtain filtrate 1, extracting with ethanol to obtain filtrate 2, and eluting the filtrate 2 with macroporous resin; adding water into the chitosan oligosaccharide and the filtrate 1 for enzymolysis; and finally, mixing the eluent and the enzymolysis liquid, drying and mixing with the fishbone powder and the hyaluronic acid. The formula sample of the invention obviously reduces the foot licking time of formalin-induced phase I and phase II pain of mice, has obvious analgesic and anti-inflammatory effects, and has the effects similar to those of common non-steroidal anti-inflammatory drugs.
Description
Technical Field
The invention belongs to the technical field of biological medicines and health care products, and particularly relates to a composition for treating osteoarthropathy and application thereof.
Background
Osteoarthritis is a degenerative joint disease in which joint cartilage is degenerated and worn, and the risk of the disease increases with age. The clinical symptoms of osteoarthritis are mainly shown in that recessive pain appears in the early stage of onset, the pain degree is strengthened after the exercise aggravates, and the pain degree is relieved after the normal state is recovered, but the pain cannot be relieved through rest along with the aggravation of the symptoms; the joint stiffness, in the morning, can cause the sensation that the joint is bound, the movement stiffness, the joint weakness and the function loss, and the pain, the joint stiffness, the joint deformation, the muscle atrophy and the like can cause the loss of the joint autonomous function along with the progress of the disease.
The main factors influencing the onset of osteoarthritis at present mainly include the following factors: (1) age, sex, race, and genetic factors; (2) people with high bone density have high possibility of generating osteoarthritis, and the increase of bone mass is positively correlated with the generation of osteoarthritis; (3) joint instability: with age or affected by disease, the nervous system's ability to control and innervate the muscles and sensations surrounding the joints decreases, the muscle forces surrounding the joints also decrease, and joint instability occurs. Unstable knee joints are prone to arthritis. (4) Nutritional deficiencies, and a doubling of the risk of osteoarthritis and pain in the knee joint if vitamin D is absent.
Current drug treatment for osteoarthritis mainly includes antipyretic, analgesic, anti-inflammatory, analgesic and nutritional supplements. These drugs can improve the clinical symptoms of the disease to a certain extent, but the non-entrapment anti-inflammatory drugs can promote the synthesis of proteoglycan in cartilage and accelerate the degeneration of articular cartilage, and long-term administration not only affects the recovery of patients, but also may aggravate the progress of the disease. In addition, there are also the medicine for intra-articular injection, glucocorticoid and sodium hyaluronate. The injection in the joints has certain trauma to the organism, is not suitable for long-term use, and hormone medicines have quick response in a short term, can cause osteoporosis after long-term use, and can aggravate the disease condition in the long run.
The side effect of the clinical medicine for treating the bone and joint pain is large, so the concept of treating the pain by traditional Chinese medicine and food therapy has great significance.
The Chinese invention patent application CN106822915A discloses a curcumin hyaluronic acid nano micelle for treating rheumatoid arthritis and a preparation method and application thereof, wherein curcumin and a hyaluronic acid solution form a compound through esterification reaction, and the nano micelle is formed by self-assembly in an aqueous solution through hydrophilic and hydrophobic acting force; and provides a preparation method and application thereof. The method has the advantages of simple preparation, no special equipment requirement, low cost, good biocompatibility of the medicine and no toxic or side effect in vivo; also has obvious effects of lubricating and protecting joints, resisting inflammation and resisting edema.
Still another chinese patent application CN106072651A discloses a composition with effects of increasing bone density, anti-inflammatory and analgesic and its preparation method, the raw material medicine components are as follows: chondroitin sulfate, glucosamine hydrochloride, calcium carbonate, sodium hyaluronate, dimethyl alkali and a kudzu root extract. Animal function tests prove that the invention can obviously improve the weight of the femur, the content of bone calcium, the femoral midpoint density and the femoral distal end bone density of a rat.
The traditional Chinese medicine and the food therapy are still auxiliary treatments in the disease remission stage, and the effects of the traditional Chinese medicine and the food therapy are still to be further improved.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a composition for treating osteoarthropathy, which has the effects of relieving and treating inflammatory reaction and pain of osteoarthropathy and can prevent diseases.
The purpose of the invention is realized by the following technical scheme:
a composition for treating osteoarthropathy comprises the following raw materials: kudzu root, turmeric, chitosan oligosaccharide, fishbone powder and hyaluronic acid/sodium hyaluronate.
Preferably, the raw materials of the composition comprise the following components in parts by weight: 20-30 parts of kudzu root, 5-10 parts of turmeric, 5-10 parts of chitosan oligosaccharide, 5-10 parts of sturgeon bone powder and 3-5 parts of hyaluronic acid/sodium hyaluronate.
Preferably, the raw materials of the composition comprise the following components in parts by weight: 24 parts of kudzu root, 6 parts of turmeric, 6 parts of chitosan oligosaccharide, 6 parts of sturgeon bone meal and 3 parts of hyaluronic acid/sodium hyaluronate.
Preferably, the mass ratio of the kudzuvine root, the turmeric and the chitosan oligosaccharide is 2-6:1-2: 1.
Preferably, the fishbone powder is sturgeon bone powder.
The sturgeon tendon is the backbone of sturgeon, has the effects of enriching blood, tonifying qi, strengthening kidney, stimulating appetite, clearing away heat and toxic materials, nourishing yin, beautifying, improving eyesight, clearing away heart-fire, moistening dryness and regulating lung, and is very effective in preventing osteoporosis and enhancing the immunity of the organism. The sturgeon bone powder selected by the invention contains rich ossein, protein and unsaturated fatty acid, and can promote the regeneration of osteocyte and protect bone blood vessel.
Still another object of the present invention is to provide a method for preparing the above composition, comprising the steps of:
(1) extracting radix Puerariae and Curcuma rhizome with water, and filtering to obtain residue 1 and filtrate 1;
(2) extracting the filter residue 1 with ethanol to obtain filtrate 2, passing the filtrate 2 through macroporous resin, eluting with water, and eluting with ethanol to obtain eluate;
(3) adding water to the chitosan oligosaccharide for swelling, then adding the chitosan oligosaccharide into the filtrate 1, stirring, carrying out enzymolysis, and filtering to obtain an enzymolysis solution;
(4) mixing the eluent and the enzymolysis liquid and drying to obtain dry paste powder;
(5) mixing the dry extract powder, fishbone powder and hyaluronic acid.
Preferably, the ratio of the mass of the water in the step (1) to the total mass of the kudzuvine root and the turmeric is 5-10: 1, the extraction time is 0.5-1h, and the extraction times are 1-3.
Preferably, the ethanol in the step (2) is 50-75% ethanol, and the mass ratio of the ethanol to the filter residue 1 is 5-8:1, the model of the macroporous resin is DM-301, the elution is sequentially performed by using 30-40% ethanol, 55-60% ethanol and 75-85% ethanol, and the eluates are combined.
Preferably, the mass of the water in the step (3) is 1-3 times of that of the chitosan oligosaccharide, and the swelling temperature is 30-50 ℃.
Preferably, the enzymes for enzymolysis are papain and cellulase.
Preferably, the mass ratio of the papain to the cellulase is 5-8: 1.
Preferably, the enzymolysis temperature is 35-45 ℃, and the enzymolysis time is 1-2.5 h; the pH value of the enzymolysis is 5.0-6.0.
The invention also aims to provide the application of the composition in preparing products for treating osteoarthropathy.
Compared with the prior art, the invention has the beneficial effects that:
(1) the traditional Chinese medicine composition disclosed by the invention achieves the effect of obviously treating inflammatory reaction and pain of bone joints by matching the kudzu root, the turmeric, the chitosan oligosaccharide, the fishbone powder and the hyaluronic acid/sodium hyaluronate according to a scientific proportion, and has the effect of quickly relieving pain in an acute stage. Compared with the common non-steroidal anti-inflammatory drugs, the traditional Chinese medicine composition has no toxic or side effect, has multiple types of active ingredients, and regulates inflammatory reaction through multiple targets.
(2) The sturgeon bone powder is adopted, so that rich calcium sources can be provided, and the sturgeon bone powder contains rich ossein, protein and unsaturated fatty acid, and can promote the regeneration of osteocytes and protect bone blood vessels. With compatibility of radix Puerariae and Curcuma rhizome, the composition can tonify blood, promote blood circulation, promote qi circulation, relieve pain, eliminate dampness, remove toxicity, and treat joint swelling and pain cooperatively.
(2) The preparation method is further researched, and research shows that the active ingredients can be fully extracted by adopting specific enzyme extraction and DM-301 resin column chromatography purification enrichment, the analgesic and anti-inflammatory effects are obviously enhanced, and the extracted active ingredients are richer.
Drawings
FIG. 1 is a graph of the effect of the compositions of the present invention on formalin-induced pain in mice;
FIG. 2 is a graph of the effect of the composition of the present invention on iodoacetic acid-induced pain in mice 3 days after administration;
figure 3 is a graph of the effect of the composition of the invention on iodoacetic acid-induced pain in mice 7 days after administration.
Detailed Description
The present invention will be further described with reference to the following embodiments.
Example 1
The composition for treating osteoarthropathy comprises the following raw material components in parts by weight: 24 parts of kudzu root, 6 parts of turmeric, 6 parts of chitosan oligosaccharide, 6 parts of sturgeon bone meal and 3 parts of hyaluronic acid.
The preparation method comprises the following steps:
(1) reflux-extracting radix Puerariae and Curcuma rhizome with water for 2 times, each for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) adding 5 times of 75% ethanol into the filter residue 1, performing reflux extraction for 1h to obtain a filtrate 2, passing the filtrate 2 through a resin DM-301 column, filling the column by a wet method, wherein the diameter-height ratio is 1:5, eluting and removing the filtrate by using 5 times of column volume of water, sequentially eluting by using 3 times of column volume of 35% ethanol, 5 times of column volume of 60% ethanol and 3 times of column volume of 80% ethanol, and merging the eluates;
(3) adding 1 time of water into chitosan oligosaccharide for swelling, adding into the filtrate 1, stirring, adding 0.3% mixture of papain and cellulase (mass ratio of 5:1), adjusting pH to 6.0, performing enzymolysis at 45 deg.C for 1 hr, boiling for 5 min to inactivate enzyme, and filtering to obtain enzymolysis solution;
(4) mixing the eluate with the enzymolysis solution, concentrating, and drying to obtain dry extract powder;
(5) mixing the dry extract powder, sturgeon bone powder and hyaluronic acid uniformly to obtain the final product.
Example 2
The composition for treating osteoarthropathy comprises the following raw material components in parts by weight: 20 parts of kudzu root, 5 parts of turmeric, 5 parts of chitosan oligosaccharide, 5 parts of sturgeon bone powder and 3 parts of hyaluronic acid.
The preparation method comprises the following steps:
(1) adding water into radix Puerariae and Curcuma rhizome, reflux extracting for 1h, and filtering to obtain residue 1 and filtrate 1;
(2) adding 8 times of 50% ethanol into the filter residue 1, performing reflux extraction for 1h to obtain a filtrate 2, enabling the filtrate 2 to pass through a resin DM-301 column, filling the column by a wet method, wherein the diameter-height ratio is 1:5, eluting and removing the filtrate by using 6 column volumes of water, sequentially eluting by using 2 times of column volumes of 40% ethanol, 6 times of column volumes of 55% ethanol and 4 times of column volumes of 75% ethanol, and merging the eluates;
(3) adding 1 time of water into chitosan oligosaccharide for swelling, adding into the filtrate 1, stirring, adding 0.5% of papain and cellulase (mass ratio of 8:1), adjusting pH to 5.0, performing enzymolysis at 35 deg.C for 2 hr, boiling for 5 min to inactivate enzyme, and filtering to obtain enzymolysis solution;
(4) mixing the eluate with the enzymolysis solution, concentrating, and drying to obtain dry extract powder;
(5) mixing the dry extract powder, sturgeon bone powder and hyaluronic acid uniformly to obtain the final product.
Example 3
The composition for treating osteoarthropathy comprises the following raw material components in parts by weight: 30 parts of kudzu root, 10 parts of turmeric, 10 parts of chitosan oligosaccharide, 9 parts of sturgeon bone powder and 5 parts of hyaluronic acid.
The preparation method comprises the following steps:
(1) extracting radix Puerariae and Curcuma rhizome with water under reflux for 3 times, each for 0.5 hr, and filtering to obtain residue 1 and filtrate 1;
(2) adding 5 times of 70% ethanol into the filter residue 1, performing reflux extraction for 1h to obtain a filtrate 2, enabling the filtrate 2 to pass through a resin DM-301 column, filling the column by a wet method, wherein the diameter-height ratio is 1:5, eluting and removing the filtrate by using 5 times of column volume of water, sequentially eluting by using 2 times of column volume of 30% ethanol, 4 times of column volume of 55% ethanol and 5 times of column volume of 75% ethanol, and combining the eluates;
(3) adding 1 time of water into chitosan oligosaccharide for swelling, adding into the filtrate 1, stirring, adding 0.2% of papain and cellulase (mass ratio of 7:1), adjusting pH to 6.0, performing enzymolysis at 40 deg.C for 1.5 hr, boiling for 5 min to inactivate enzyme, and filtering to obtain enzymolysis solution;
(4) mixing the eluate with the enzymolysis solution, concentrating, and drying to obtain dry extract powder;
(5) mixing the dry extract powder, sturgeon bone powder and hyaluronic acid uniformly to obtain the final product.
Comparative example 1
The comparative example is different from example 1 in the component raw materials, and specifically comprises the following steps: 30 parts of kudzu root, 6 parts of chitosan oligosaccharide, 6 parts of sturgeon bone powder and 3 parts of hyaluronic acid.
The preparation method comprises the following steps:
(1) extracting radix Puerariae with water under reflux for 2 times, each for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) adding 75% ethanol into the filter residue 1, performing reflux extraction for 1h to obtain a filtrate 2, passing the filtrate 2 through a resin DM-301 column, performing wet column packing with a diameter-height ratio of 1:5, eluting and removing with 5 column volumes of water, sequentially eluting with 3 times of 35% ethanol, 5 times of 60% ethanol and 3 times of 80% ethanol, and mixing the eluates;
(3) adding 1 time of water into chitosan oligosaccharide for swelling, adding into the filtrate 1, stirring, adding 0.3% of papain and cellulase (mass ratio of 5:1), adjusting pH to 6.0, performing enzymolysis at 45 deg.C for 1h, boiling for 5 min to inactivate enzyme, and filtering to obtain enzymolysis solution;
(4) mixing the eluate with the enzymolysis solution, concentrating, and drying to obtain dry extract powder;
(5) mixing the dry extract powder, sturgeon bone powder and hyaluronic acid uniformly to obtain the final product.
Comparative example 2
The comparative example is different from example 1 in the component raw materials, and specifically comprises the following steps: 30 parts of turmeric, 6 parts of chitosan oligosaccharide, 6 parts of sturgeon bone meal and 3 parts of hyaluronic acid.
The preparation method comprises the following steps:
(1) extracting Curcuma rhizome with water under reflux for 2 times, each for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) adding 75% ethanol into the filter residue 1, performing reflux extraction for 1h to obtain a filtrate 2, passing the filtrate 2 through a resin DM-301 column, performing wet column packing with a diameter-height ratio of 1:5, eluting and removing with 5 column volumes of water, sequentially eluting with 3 times of 35% ethanol, 5 times of 60% ethanol and 3 times of 80% ethanol, and mixing the eluates;
(3) adding 1 time of water into chitosan oligosaccharide for swelling, adding into the filtrate 1, stirring, adding 0.3% of papain and cellulase (mass ratio of 5:1), adjusting pH to 6.0, performing enzymolysis at 45 deg.C for 1h, boiling for 5 min to inactivate enzyme, and filtering to obtain enzymolysis solution;
(4) mixing the eluate with the enzymolysis solution, concentrating, and drying to obtain dry extract powder;
(5) mixing the dry extract powder, sturgeon bone powder and hyaluronic acid uniformly to obtain the final product.
Comparative example 3
This comparative example is different from the preparation method of example 1, specifically, HPD-300 is used as the macroporous resin of step (2), and the rest is the same as example 1.
The preparation method comprises the following steps:
(1) reflux-extracting radix Puerariae and Curcuma rhizome with water for 2 times, each for 1 hr, filtering to obtain residue 1 and filtrate 1;
(2) adding 75% ethanol into the filter residue 1, performing reflux extraction for 1h to obtain a filtrate 2, passing the filtrate 2 through a resin HPD-300 column, filling the column by a wet method, wherein the diameter-height ratio is 1:5, eluting and removing the filtrate by using 5 column volumes of water, sequentially eluting by using 3 times of column volumes of 35% ethanol, 5 times of column volumes of 60% ethanol and 3 times of column volumes of 80% ethanol, and merging the eluates;
(3) adding 1 time of water into chitosan oligosaccharide for swelling, adding into the filtrate 1, stirring, adding 0.3% of papain and cellulase (mass ratio of 5:1), adjusting pH to 6.0, performing enzymolysis at 45 deg.C for 1h, boiling for 5 min to inactivate enzyme, and filtering to obtain enzymolysis solution;
(4) mixing the eluate with the enzymolysis solution, concentrating, and drying to obtain dry extract powder;
(5) mixing the dry extract powder, sturgeon bone powder and hyaluronic acid uniformly to obtain the final product.
Comparative example 4
The difference between the comparative example and the example 1 is that the preparation method is different, and specifically, the enzyme adopted in the enzymolysis in the step (3) is formed by compounding ficin, bromelain and cellulase in a mass ratio of 2:3: 1.
The preparation method comprises the following steps:
(1) extracting radix Puerariae and Curcuma rhizome with water under reflux for 2 times, each for 1 hr, filtering to obtain residue 1 and filtrate 1;
(2) adding 75% ethanol into the filter residue 1, performing reflux extraction for 1h to obtain a filtrate 2, passing the filtrate 2 through a resin DM-301 column, performing wet column packing with a diameter-height ratio of 1:5, eluting and removing with 5 column volumes of water, sequentially eluting with 3 times of 35% ethanol, 5 times of 60% ethanol and 3 times of 80% ethanol, and mixing the eluates;
(3) adding 1 time of water into chitosan oligosaccharide for swelling, adding into the filtrate 1, stirring, adding 0.3% of ficin, bromelin and cellulase (mass ratio is 2:3:1), adjusting pH to 6.0, performing enzymolysis at 45 deg.C for 1 hr, boiling for 5 min to inactivate enzyme, and filtering to obtain enzymolysis solution;
(4) mixing the eluate with the enzymolysis solution, concentrating, and drying to obtain dry extract powder;
(5) mixing the dry extract powder, sturgeon bone powder and hyaluronic acid uniformly to obtain the final product.
Test 1 Effect of the present invention on formalin-induced pain in mice
110 SPF grade C57 mice, male, 22-24 g, randomly divided into 11 groups of 10 mice each, negative group of mice given solvent; example 1 the low dose group (50mg/kg), the medium dose group (100mg/kg), the high dose group (200mg/kg), the example 2(200mg/kg), the example 3 group (200mg/kg), the positive group were given the nsaid granules (0.16g/kg), the comparative examples 1-4 groups (200mg/kg), the samples were mixed and 0.5% CMC was added, sonicated for 1 minute, and diluted to the desired concentration for use. The administration is carried out once a day for 14 days.
30 minutes after the last administration, the mouse was injected with 20ul of 1% formalin subcutaneously into the toes, immediately placed in a beaker, continuously photographed by a camera for 60 minutes, and the time for the mouse to lick the feet was counted. The effect of the low, medium and high dose groups on the inflammatory pain licking time in mice in the negative group is shown in fig. 1, and the measured values in the remaining examples, positive group and comparative group are shown in table 1.
TABLE 1 Effect of formula samples on formalin-induced pain and inflammation
Note: in the same column, each group was compared with the negative group, * P＜0.05； ** P＜0.01。
and (4) analyzing results: mice developed phase I pain (0-15 min) with predominantly nociceptive stimulation and phase II pain (16-45 min) with predominantly inflammatory pain following plantar formalin injection. From the results in fig. 1, the formula sample significantly reduces the foot licking time of the phase I and phase II pain of the mice, which indicates that the sample has significant analgesic and anti-inflammatory effects. The comparative examples 1 and 2 adopt a medicine-lacking formula, the comparative example 3 adopts an unreasonable proportion, and the comparative example 4 adopts other preparation methods, so that the effects of mice on formalin-induced pain and inflammation are remarkably poor on the premise of equal dosage administration.
Animals and grouping:
110 SPF grade C57 mice, male, 22-24 g, randomly divided into 11 groups of 10 mice each, model group mice given solvent; example 1 the low dose group (50mg/kg), the medium dose group (100mg/kg), the high dose group (200mg/kg), the example 2(200mg/kg), the example 3 group (200mg/kg), the positive group were given the nsaid granules (0.16g/kg), the comparative examples 1-4 groups (200mg/kg), the samples were mixed, added with 0.5% CMC as a solvent, sonicated for 1 minute, and diluted to the desired concentration for use. The administration is carried out once a day for 14 days.
30 minutes after the last administration, the mice were anesthetized and then the joint hairs were removed, and the microinjector injected with iodoacetic acid (10mg/ml, 10ul) into the joint cavity. Control groups were injected with PBS. The influence of the formulation on the pain of the mice is detected by a plantar dynamic tactile meter after 3 days and 7 days of iodoacetic acid injection respectively. The effect of the model group on the mechanical stimulation pain in the soles of the mice in the low, medium and high dose groups as in example 1 is shown in FIGS. 2 to 3, and the measured values of the remaining examples, positive groups and comparative groups are shown in Table 2.
TABLE 2 Effect of formulation samples on Iodoacetic acid-induced pain
Note: same column, comparing with model group, P < 0.05, P < 0.01; in comparison with the high dose group of example 1, # P＜0.05。
and (4) analyzing results: after 3 days (mainly nociceptive pain) and 7 days (mainly inflammatory-response pain) of iodoacetic acid induction, the sole dynamic tactile meter was used to detect the effect of the sole on the mechanical stimulation pain. As can be seen from fig. 2-3 and table 1, formulation samples of the present invention at different doses significantly increased the mouse irritation pain threshold on both day 3 and day 7 compared to the model group. Indicating that the medicine has a therapeutic effect on pain and inflammation induced by iodoacetic acid.
Because the comparative example 1 and the comparative example 2 adopt the medicine-lacking formula, the comparative example 3 adopts unreasonable proportion, and the comparative example 4 adopts other preparation methods, the effect of the mice on the pain and inflammation induced by the iodoacetic acid is worse than that of the invention under the premise of equal dosage administration.
The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.
Claims (10)
1. The composition for treating osteoarthropathy is characterized in that the raw materials of the composition comprise the following components: kudzu root, turmeric, chitosan oligosaccharide, fishbone powder and hyaluronic acid/sodium hyaluronate.
2. The composition according to claim 1, wherein the composition comprises the following raw materials in parts by weight: 20-30 parts of kudzu root, 5-10 parts of turmeric, 5-10 parts of chitosan oligosaccharide, 5-10 parts of sturgeon bone powder and 3-5 parts of hyaluronic acid/sodium hyaluronate.
3. The composition according to claim 1, wherein the composition comprises the following raw materials in parts by weight: 24 parts of kudzu root, 6 parts of turmeric, 6 parts of chitosan oligosaccharide, 6 parts of sturgeon bone powder and 3 parts of hyaluronic acid/sodium hyaluronate.
4. The composition as claimed in claim 1, wherein the mass ratio of pueraria lobata, curcuma longa and chitosan oligosaccharide is 2-6:1-2: 1.
5. The composition according to claim 1, wherein the fishbone powder is sturgeon bone powder.
6. A process for preparing a composition according to any one of claims 1 to 5, comprising the steps of:
(1) extracting radix Puerariae and Curcuma rhizome with water, and filtering to obtain residue 1 and filtrate 1;
(2) extracting the filter residue 1 with ethanol to obtain filtrate 2, passing the filtrate 2 through macroporous resin, eluting with water, and eluting with ethanol to obtain eluate;
(3) adding water to swell chitosan oligosaccharide, adding the chitosan oligosaccharide into the filtrate 1, stirring, performing enzymolysis, and filtering to obtain an enzymolysis solution;
(4) mixing the eluate and the enzymolysis solution, and drying to obtain dry extract powder;
(5) mixing the dry extract powder, fishbone powder and hyaluronic acid/sodium hyaluronate.
7. The preparation method according to claim 6, wherein the ethanol in the step (2) is 50-75% ethanol, and the mass ratio of the ethanol to the residue 1 is 5-8:1, the model of the macroporous resin is DM-301, the elution is sequentially eluted by 30-40% ethanol, 55-60% ethanol and 75-85% ethanol, and the eluates are combined.
8. The preparation method according to claim 6, wherein the mass of the water in the step (3) is 1-3 times of that of the chitosan oligosaccharide, the swelling temperature is 30-50 ℃, the enzymes for enzymolysis are papain and cellulase, the enzymolysis temperature is 35-45 ℃, and the enzymolysis time is 1-2.5 hours; the pH value of the enzymolysis is 5.0-6.0.
9. The method according to claim 8, wherein the mass ratio of papain to cellulase is 5-8:1, and the mass of the enzyme added for enzymolysis is 0.2-0.5% of the mass of the filtrate 1.
10. Use of a composition according to any one of claims 1 to 5 for the preparation of a product for the treatment of osteoarthrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210531563.8A CN114903961A (en) | 2022-05-16 | 2022-05-16 | Composition for treating osteoarthropathy and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210531563.8A CN114903961A (en) | 2022-05-16 | 2022-05-16 | Composition for treating osteoarthropathy and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114903961A true CN114903961A (en) | 2022-08-16 |
Family
ID=82767687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210531563.8A Pending CN114903961A (en) | 2022-05-16 | 2022-05-16 | Composition for treating osteoarthropathy and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114903961A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115500513A (en) * | 2022-10-20 | 2022-12-23 | 洛阳清奇古怪生物科技有限公司 | Combined formula for joint protection |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014138372A1 (en) * | 2013-03-06 | 2014-09-12 | Primavera Biosciences, Inc. | Composition and method for treating osteoarthritis |
| CN106135891A (en) * | 2015-04-15 | 2016-11-23 | 吉林省中医药科学院 | A kind of health food to alcoholic liver injury with defencive function |
| CN106721699A (en) * | 2016-11-30 | 2017-05-31 | 江苏食品药品职业技术学院 | A kind of sobering-up beverage and preparation method thereof |
| CN109453342A (en) * | 2018-12-26 | 2019-03-12 | 无限极（中国）有限公司 | A kind of Chinese medicine composition and application, preparation method, health food with joint protection effect |
| CN112079913A (en) * | 2020-09-25 | 2020-12-15 | 康洛信(广东)生物科技有限公司 | Process for extracting non-denatured type II collagen from sturgeon cartilage |
| CN112807416A (en) * | 2021-01-18 | 2021-05-18 | 宁波御坊堂生物科技有限公司 | Traditional Chinese medicine bone peptide composition with function of improving bone joint health and preparation method thereof |
-
2022
- 2022-05-16 CN CN202210531563.8A patent/CN114903961A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014138372A1 (en) * | 2013-03-06 | 2014-09-12 | Primavera Biosciences, Inc. | Composition and method for treating osteoarthritis |
| CN106135891A (en) * | 2015-04-15 | 2016-11-23 | 吉林省中医药科学院 | A kind of health food to alcoholic liver injury with defencive function |
| CN106721699A (en) * | 2016-11-30 | 2017-05-31 | 江苏食品药品职业技术学院 | A kind of sobering-up beverage and preparation method thereof |
| CN109453342A (en) * | 2018-12-26 | 2019-03-12 | 无限极（中国）有限公司 | A kind of Chinese medicine composition and application, preparation method, health food with joint protection effect |
| CN112079913A (en) * | 2020-09-25 | 2020-12-15 | 康洛信(广东)生物科技有限公司 | Process for extracting non-denatured type II collagen from sturgeon cartilage |
| CN112807416A (en) * | 2021-01-18 | 2021-05-18 | 宁波御坊堂生物科技有限公司 | Traditional Chinese medicine bone peptide composition with function of improving bone joint health and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115500513A (en) * | 2022-10-20 | 2022-12-23 | 洛阳清奇古怪生物科技有限公司 | Combined formula for joint protection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105434465B (en) | It is a kind of to prevent and treat arthritic pharmaceutical composition and preparation method thereof | |
| CN108420826B (en) | Application of lycium barbarum polysaccharide in preparation of medicine for treating or relieving depression and pharmaceutical composition containing lycium barbarum polysaccharide | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN107349333B (en) | Composition with effect of increasing bone mineral density and preparation method and application thereof | |
| CN114903961A (en) | Composition for treating osteoarthropathy and application thereof | |
| CN113797215B (en) | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof | |
| CN115252692A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating diseases related to hyperuricemia | |
| CN101167937A (en) | Traditional Chinese medicinal composition plaster for curing rheumatism or rheumatoid diseases and preparation method thereof | |
| CN106333977B (en) | Natural pharmaceutical composition for treating osteoporotic fracture and/or osteoarthritis and application thereof | |
| CN114042146A (en) | Bovine bone peptide composition and application thereof in preparing medicines for regulating intestinal flora and preventing and treating osteoporosis | |
| CN108354898A (en) | A kind of Percutaneously administrable preparation and preparation method thereof for treating rheumatoid arthritis | |
| KR100786122B1 (en) | Composition effective for prevention and treatment of obesity which contains crude drug extract | |
| WO2004014406A1 (en) | Use of fermented wheat germ extract as anti-inflammatory agent | |
| CN112315916B (en) | Traditional Chinese medicine granules for treating osteoarthritis and preparation method thereof | |
| CN113413395A (en) | Composition containing pinoresinol diglucoside and preparation method and application thereof | |
| CN113663010A (en) | Compound traditional Chinese medicine composition and application thereof in preparation of medicine for treating fatty liver | |
| KR101911877B1 (en) | Functional food composition comprising herbal medicinal extracts | |
| CN107982409B (en) | Traditional Chinese medicine composition and pill for treating syringomyelia and preparation method thereof | |
| CN109125631A (en) | Chinese medicine composition and preparation method thereof with liver kidney regulatory function | |
| CN105770864A (en) | Composition with function of relieving joint inflammation pain | |
| Suhih et al. | Perspective natural sources of chondroprotectors | |
| CN1177592C (en) | Myocarditis treating medicine | |
| US20050266106A1 (en) | Use of fermented wheat germ extract as anti-inflammatory agent | |
| CN100339133C (en) | Composition of nanometer SOD and astragalus root or its extract and its preparation method | |
| Osfor | Some biochemical and nutritional studies on the effect of Panax ginseng powder extract on adult Japanese quails |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |